Europe Semaglutide Market Size & Outlook, 2024-2035
Related Markets
Europe semaglutide market highlights
- The Europe semaglutide market generated a revenue of USD 3,885.3 million in 2024.
- The market is expected to grow at a CAGR of 12% from 2025 to 2035.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2024.
- Rybelsus (oral semaglutide) is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Spain is expected to register the highest CAGR from 2025 to 2035.
Europe data book summary
| Market revenue in 2024 | USD 3,885.3 million |
| Market revenue in 2035 | USD 16,812.0 million |
| Growth rate | 12% (CAGR from 2025 to 2035) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Rybelsus (oral semaglutide) |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2035 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
Other key industry trends
- In terms of revenue, Europe region accounted for 13.7% of the global semaglutide market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2035.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,055.5 million by 2035.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Semaglutide Market Scope
Semaglutide Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lexicon Pharmaceuticals | View profile | 101-250 | The Woodlands, Texas, United States, North America | http://www.lexpharma.com |
| Viking Therapeutics Inc | View profile | 28 | 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, United States, 92121 | https://www.vikingtherapeutics.com |
| Biocon | View profile | 10001+ | Bangalore, Karnataka, India, Asia | http://www.biocon.com |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Novo Nordisk A/S ADR | View profile | 66015 | Novo Alle 1, Bagsvaerd, Denmark, 2880 | https://www.novonordisk.com |
| Eli Lilly and Co | View profile | 43000 | Lilly Corporate Center, Indianapolis, IN, United States, 46285 | https://www.lilly.com |
Europe semaglutide market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 57.43% in 2024. Horizon Databook has segmented the Europe semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Europe exhibits steady semaglutide market growth, led by Germany, France, and the UK. The region benefits from strong clinical research infrastructure, government initiatives for obesity and diabetes management, and increasing prescriptions of GLP-1 receptor agonists. Regulatory policies supporting obesity therapeutics further drive adoption.
Reasons to subscribe to Europe semaglutide market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe semaglutide market databook
-
Our clientele includes a mix of semaglutide market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe semaglutide market , including forecasts for subscribers. This continent databook contains high-level insights into Europe semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
Partial client list
Europe semaglutide market size, by country, 2018-2035 (US$M)
Europe Semaglutide Market Outlook Share, 2024 & 2035 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
